Skip to main
DWTX

DWTX Stock Forecast & Price Target

DWTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dogwood Therapeutics Inc. is positioned for growth, having raised its estimated revenue projections due to a new asset, leading to a revised price expectations from $10.00 to $12.00 per share. The recent licensing agreement with Serpin Pharma for the global rights to SP16, targeted at cancer-related pain, further enhances the company’s portfolio and revenue potential. Additionally, Dogwood's focus on innovative antiviral therapies targeting viruses linked to immune response disorders like fibromyalgia and long COVID signals a robust pipeline that could position it favorably in the biotechnology market.

Bears say

Dogwood Therapeutics Inc, previously known as Virios Therapeutics Inc, operates as a development-stage biotechnology firm focused on creating antiviral therapies for conditions linked to abnormal immune responses, primarily fibromyalgia and long COVID. The company’s current product candidates, IMC-1 and IMC-2, are aimed at addressing herpesvirus-related issues; however, the financial health and viability of Dogwood Therapeutics remain uncertain due to a lack of substantial revenue generation and ongoing expenses typical of early-stage companies. Additionally, the challenges of advancing drug candidates through clinical trials and the competitive landscape within the biotechnology sector contribute to a cautious outlook for the company's stock performance and investor confidence.

DWTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dogwood Therapeutics, Inc. (DWTX) Forecast

Analysts have given DWTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, DWTX has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dogwood Therapeutics, Inc. (DWTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.